THE 3rd EURL-AR PROFICIENCY TEST ON SELECTIVE ISOLATION OF E. COLI WITH PRESUMPTIVE ESBL OR AMPC PHENOTYPES FROM MEAT OR CAECAL SAMPLES - 2017

Jette Sejer Kjeldgaard
Susanne Karlsnose Pedersen
Rene S. Hendriksen
Valeria Bortolaia
THE 3rd EURL-AR PROFICIENCY TEST ON SELECTIVE ISOLATION OF ESCHERICHIA COLI WITH PRESUMPTIVE ESBL OR AMPC PHENOTYPES FROM MEAT AND CAECAL SAMPLES - 2017

December 2018
Copyright: National Food Institute, Technical University of Denmark
Photo: Lina Cavaco
ISBN: 978-87-93565-35-7

This report is available at
www.food.dtu.dk

National Food Institute
Technical University of Denmark
Kemitorvet
Building 202
DK-2800 Kgs.Lyngby
Tel: +45 35 88 70 00
Fax: +45 35 88 70 01
Index

Index ........................................................................................................................................................... 3  
1. Introduction ............................................................................................................................................. 4  
2. Materials and Methods ........................................................................................................................... 5  
  2.1 Participants in EQAS 2017 .............................................................................................................. 5  
  2.2 Preparation of samples .................................................................................................................... 5  
  2.3 Isolation and identification of ESBL, AmpC or carbapenemase producing E. coli from meat and caecal samples ....................................................................................................................................... 7  
  2.4 Antimicrobial susceptibility testing .................................................................................................... 7  
  2.5 Distribution ....................................................................................................................................... 7  
  2.6 Procedure ......................................................................................................................................... 8  
3. Results .................................................................................................................................................... 9  
  3.1 Data omitted from the report ............................................................................................................ 9  
  3.2 Methods used by EQAS-participants ............................................................................................. 10  
  3.3 ESBL /AmpC and carbapenemase producing E. coli isolation and identification ......................... 11  
  3.4 Antimicrobial susceptibility testing .................................................................................................. 11  
  3.5 ESBL/AmpC phenotypic testing conclusions ................................................................................ 13  
4. Discussion ............................................................................................................................................ 14  
  4.1 ESBL and AmpC and carbapenemase-producing E. coli isolation and identification .................. 14  
  4.2 Antimicrobial susceptibility testing .................................................................................................. 14  
  4.3 ESBL /AmpC phenotypic testing conclusions ................................................................................ 14  
5. Conclusion ............................................................................................................................................ 15  
6. References ........................................................................................................................................... 15  

Appendix 1. Pre-notification EUR-AR EQAS matrix 2017  
Appendix 2. List of participants  
Appendix 3. Expected results  
Appendix 4. Protocol EQAS matrix 2017  
Appendix 5. Examples of Test forms EQAS matrix 2017
1. Introduction

This report describes and summarises results from the third matrix-based proficiency test conducted by The National Food Institute (DTU Food) as the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR) as an External Quality Assurance System (EQAS). This proficiency test focuses on selective isolation of extended spectrum beta-lactamase (ESBL) and AmpC-producing *E. coli* from meat and caecal samples of animal origin and antimicrobial susceptibility testing (AST) of the isolated *E. coli*. In addition, the proficiency test includes optional isolation of carbapenemases and OXA-48-producing *E. coli*.

Extended spectrum beta-lactamase (ESBL) and AmpC-producing *E. coli* continue to spread in food producing animals. In 2013, the European Commission (EC) decided to include the isolation of ESBL and AmpC-producing *E. coli* as mandatory parts of the EU monitoring and this started during 2015. The screening includes matrix samples consisting of either meat or caecal samples of animal origin in the EU Member States (MS) and affiliated countries according to a common protocol defined by the EC and validated by the EURL-AR (EURL-AR, 2017).

In 2016 the EQAS was extended also to include carbapenemase and/or OXA-48-producing *E. coli*, thereby including the optional isolation of these using the EURL-AR selective isolation protocol on agar plates suitable for isolation of carbapenemase-producing *E. coli* (EURL-AR, 2017).

Similar to the previous EURL-AR matrix based EQAS’, the aim of this specific EQAS was to i) monitor the capacity of the National Reference Laboratories (NRL-AR) for isolation, identification and AST of ESBL/AmpC or carbapenemase-producing *E. coli*, ii) identify laboratories which may need assistance to improve their performance in isolation and AST of *E. coli* from matrices, and iii) identify potential problems or focus areas for future training and research.

From January 2016, the laboratories should have implemented the methods and have started the monitoring on meat and caecal samples of poultry origin. The participation in this EQAS may be used to assess retrospectively the quality of data provided to the European Food Safety Agency (EFSA).

In reading this report, the following important considerations should be taken into account:

1) Expected results were generated by performing Minimum Inhibitory Concentration (MIC) determination for all test strains prior to selection of strains and MIC’s were confirmed upon selection of strains at the Technical University of Denmark, National Food Institute (DTU Food). The genetic basis for resistance was known, as all the selected test strains had been whole-genome sequenced (WGS). The MIC determination was repeated after preparation of the matrix samples of meat and caecal, which revealed a risk for deviating phenotypic results (See section 3.1).

2) No thresholds have been set in advance to evaluate the acceptance of the performance of the participating laboratories and therefore the results will not be classified as above or below a threshold, but evaluated case by case.

3) Evaluation of a result as ‘deviating from the expected interpretation’ should be carefully analysed in a self-evaluation performed by the participant, including considerations of corrective actions in the laboratory. Note that since methods used for MIC determination has limitations, it is not considered a mistake to obtain a one-fold dilution difference in the MIC of a specific antimicrobial when testing the
same strains. If, however, the expected MIC is close to the breakpoint value for categorising the strain as susceptible or resistant, one two-fold dilution difference (which is acceptable) may result in two different interpretations, i.e. the same strain can be categorized as susceptible and resistant. This result will be evaluated as correct in one case, but incorrect when the evaluation is based on AST interpretations. In the organization of the EQAS, we try to avoid these situations by choosing test strains with MIC values distant from the cut-offs for resistance, which is not always feasible for all strains and all antimicrobials. Therefore, the EURL-AR network unanimously established in 2008 that if there are less than 75% correct results for a specific strain/antimicrobial combination, the reasons for this situation must be further examined and, on selected occasions explained in details case by case, these results may subsequently be omitted from the evaluation report.

The data in this report is presented with laboratory codes. A laboratory code is known only by the individual laboratory, whereas the entire list of laboratories and their codes is confidential and known only by relevant representatives of the EURL-AR and the EU Commission. All conclusions are public.

This third matrix EQAS was organized by the EURL-AR at the National Food Institute (DTU Food), Kgs. Lyngby, Denmark. The report is approved in its final version by a technical advisory group composed by competent representatives from all NRL-ARs, who meets annually at the EURL-AR workshop.

2. Materials and Methods

2.1 Participants in EQAS 2017

A pre-notification (App. 1), announcing the matrix EQAS 2017, was distributed on the 3rd of August 2017 by e-mail to the designated NRLs including all EU countries and Iceland, Norway and Switzerland. In total 35 laboratories participated in the matrix EQAS (App. 2) involving one NRL from each of the 28 MS (two from two countries, analysing meat and caecal sample in different laboratories), and from Iceland, Norway and Switzerland, plus additional laboratories. As results from only one laboratory per country are included in this report, 33 laboratory results from 31 countries are described. The exception was the two countries, who has different laboratories enrolled for handling meat and caecal samples, and therefore had two different NRLs enrolled.

Furthermore, one additional laboratory from each of the Netherlands, Spain and United Kingdom participated. These were invited based on their participation in previous EQAS iterations and/or affiliation to the EU network and provided results but were not included further in the report. Participants from non-EU MS were charged a fee for participation whereas participation was free of charge for EU MS, but each laboratory was expected to cover expenses associated with the analyses. The European countries participating are marked on map in Figure 1.

2.2 Preparation of samples

Eight samples were prepared and dispatched for isolation of ESBL, AmpC or carbapenemase-producing E. coli, including identification, and antimicrobial susceptibility testing (AST) of the obtained isolates. The samples included five bovine meat and three pig caecal samples and were either prepared by spiking with test strains or unmodified.
The meat used to prepare the samples was minced beef meat of Danish origin (born, raised, slaughtered and packed in Denmark) acquired in local supermarkets (at least three batches were bought in sufficient amount for covering both the pre-tests and preparation of the samples). The meat was pretested using the official method for selective isolation of \textit{E. coli} producing ESBL, AmpC or carbapenemase to ensure the batch used was negative for those and contained some background flora. A batch fulfilling these criteria was chosen for preparation of aliquots of 25 g of meat that were either used directly as blank samples or spiked as follows.

The test isolates used in the spiking of meat samples within the EQAS matrix 2017 were prepared in advance and sub-cultured the day before sample preparation. For the sample preparation and standardization of the spiking, suspensions equal to McFarland 0.5 were prepared in saline tubes with the relevant isolates to contain about $10^8$ CFU/mL, as confirmed by viable counts of serial dilutions on Luria Bertani (LB) agar plates. The standardized suspensions were further diluted in ten-fold dilutions and the meat samples (25 g) were spiked with 25 µl of the chosen dilutions. The spiking dilutions were chosen based on the results obtained in the previous matrix EQAS 2016 and a prior pilot test. The final inoculum found in the samples in this EQAS was expected to be approx. $10^5$ CFU/g meat, for the samples EURL-M-3.2, M-3.3, M-3.4 and M-3.5, whereas the sample M-3.1 was spiked with a lower amount of about 100 CFU/g meat of the test strain. The sample M-3.2 was spiked as mentioned above, however with a susceptible \textit{E. coli} strain (ATCC 25922) and therefore expected to be negative.

For the caecal samples, previous testing showed instability of ESBL \textit{E. coli} inoculum in pig caecal (matrix EQAS 2015), thus a pilot test was initially conducted. The pilot aimed both to ensure that we could obtain ESBL-negative caecal material, but also to identify ESBL/AmpC producing \textit{E. coli} isolates capable of surviving as inoculum in the caecal samples, in the period needed to ship and analyse samples. One slaughterhouse provided on Oct. 2nd ten pig caecal samples from different herds. These samples were tested individually using the official selective isolation protocol for ESBL, AmpC and carbapenemase-producing \textit{E. coli}.

Two of the caecal samples were found to contain presumptive ESBL producing \textit{E. coli}, and these isolates were included in the stability test, together with five \textit{E. coli} from the EURL-AR strain collection, originally deriving from pig caecal. One ESBL-negative caecal batch was chosen for individual inoculation of a total of seven test strains (10 µl inoculum in 1 g caecal sample for a final inoculum of approx. $10^4$ CFU/g), and their viability was evaluated in up to ten days. Two ESBL-producing \textit{E. coli} were chosen as the final test strains.

On Oct. 30th, additional 10 pig caecal samples were obtained at one slaughterhouse, for the final preparation of the matrix samples. These samples were likewise tested individually for natural occurrence of ESBL, AmpC and carbapenemase-producing \textit{E. coli}. One negative caecal batch was chosen for preparation of the matrix caecal samples for the
EQAS. Thereby 1 g aliquots of caecal content was spiked with 10 μl of a dilution containing 10^5 CFU/ml, causing an expected spiking level of 10^4 CFU/g for the samples M-3.6 and M-3.7, while sample M-3.8 was kept as blank.

The minimal inhibitory concentrations (MIC) of selected antimicrobials were determined using broth microdilution method both for the strains used for spiking during the preparation work and for the isolates obtained in the homogeneity testing after sample preparation to generate expected results (App. 3).

For follow-up on the stability of the inoculum in the matrix samples after shipping, repeated testing was performed on sets the eight samples in four time points after shipment (during two weeks). In this period the meat and caecal samples were kept at 4°C, to mimic the conditions in the shipment parcel.

2.3 Isolation and identification of ESBL, AmpC or carbapenemase producing E. coli from meat and caecal samples

The official protocols for selective isolation and identification of the ESBL, AmpC and/or carbapenemase-producing E. coli isolates contained in the samples were available on the EUURL website, http://www.eurl-ar.eu (App. 4). For the confirmation of E. coli isolates, different methods were allowed as these are not specified in the legislation (EU Commission implementing decision on the monitoring and reporting antimicrobial resistance in zoonotic and commensal bacteria 2013/652/EU). The description of the method used for selective isolation of presumptive ESBL, AmpC or carbapenemase-producing E. coli as well as species identification was requested as part of the methods sheet to be completed in the database upload system.

2.4 Antimicrobial susceptibility testing

The panels of antimicrobials recommended for AST in this proficiency test are those included in the EU Commission implementing decision on the monitoring and reporting Antimicrobial resistance in zoonotic and commensal bacteria 2013/652/EU (Table 1).

Guidelines for performing the antimicrobial susceptibility testing using dilution methods were set according to the Clinical and Laboratory Standards Institute (CLSI) document – M7-A10 (2015) "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard - tenth Edition” and whenever commercial methods were used, the guidelines of the manufacturer were followed.

MIC results were interpreted by using EUCAST epidemiological cut-off values (www.eucast.org), as included in the regulation referred above or as recommended by EFSA and described in the EQAS protocol (App. 4). Results of the ESBL confirmatory testing were interpreted according to the recommendations by EFSA and as referred in the regulation, using MIC testing on the second panel of antimicrobials, which is intended to be used every time a strain is found resistant to either cefotaxime, ceftazidime or meropenem.

2.5 Distribution

The meat samples were frozen at -80°C and kept at this temperature after preparation and until the time for shipment. The caecal samples were sent shortly after preparation, and therefore kept at 4°C until the time for shipment. At the day of shipment, the samples were tightly packed in thermoboxes with cooling elements, frozen at -80°C. The parcels contained the eight samples in tubes, and an additional tube contained a temperature logger to register the temperature at 15 min intervals during transport. Furthermore, the parcel contained a
welcome letter with the login and password to
the online database for the data upload and a
labelled envelope for returning the temperature
logger to the EURL-AR.

The protocol for the EQAS and the test forms
were made available online on the EURL-AR
website, http://www.eurl-ar.eu before launching
this EQAS.

The thermoboxes used for the shipment of
samples were enclosed in double pack
containers and sent to the selected laboratories
according to the International Air Transport
Association (IATA) regulations as “Biological
Substance category B” classified UN3373. The
parcels were dispatched from DTU-Food

2.6 Procedure

The laboratories were instructed to download
the protocol and test forms (App. 4 and 5), from
http://www.eurl-ar.eu and to process the
samples following the EU protocol for selective
isolation of presumptive ESBL, AmpC and/
carbapenemase producing E. coli from either
meat or caecal samples, precisely as they
would normally do for the EFSA monitoring. For
the results collection the NRLs were instructed
to upload of the data in the web based
database, which was designed and prepared
for this EQAS and opened after sample
shipment and until the deadline.

After completion of the tests, the laboratories
were requested to enter the obtained results
into the electronic sheet in the EURL-AR web
based database through a secured individual
login (App 5). The database was activated on
the 28th of November 2017, and was closed
December 29th 2017.

For the first part of the results of the selective
isolation procedure for ESBL /AmpC and for
carbapenemases, the results obtained from the
isolation procedures samples were evaluated
separately by defining the samples as positive if
an isolate was obtained and positively identified
as E. coli. Additionally, the results of
susceptibility testing of the obtained isolates
using both MIC panels were analysed
separately in similar way as to the similarly to
the E. coli AST EQAS, including the read
values of MIC and their interpretations. As a

<table>
<thead>
<tr>
<th>Escherichia coli EUVEC</th>
<th>Escherichia coli EUVEC2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampicillin, AMP</td>
<td>Cefepime, FEP</td>
</tr>
<tr>
<td>Azithromycin, AZI</td>
<td>Cefotaxime + clavulanic acid (F/C)</td>
</tr>
<tr>
<td>Cefotaxime, FOT</td>
<td>Cefotaxime, FOT</td>
</tr>
<tr>
<td>Ceftazidime, TAZ</td>
<td>Cefoxitin, FOX</td>
</tr>
<tr>
<td>Chloramphenicol, CHL</td>
<td>Ceftazidime, TAZ</td>
</tr>
<tr>
<td>Ciprofloxacin, CIP</td>
<td>Ceftazidime + clavulanic acid (T/C)</td>
</tr>
<tr>
<td>Colistin, COL</td>
<td>Ertapenem, ETP</td>
</tr>
<tr>
<td>Gentamicin, GEN</td>
<td>Imipenem, IMI</td>
</tr>
<tr>
<td>Meropenem, MERO</td>
<td>Meropenem, MERO</td>
</tr>
<tr>
<td>Nalidixic acid, NAL</td>
<td>Temocillin, TRM</td>
</tr>
<tr>
<td>Sulfamethoxazole, SMX</td>
<td></td>
</tr>
<tr>
<td>Tetracycline, TET</td>
<td></td>
</tr>
<tr>
<td>Tigecycline, TGC</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Panel of antimicrobials recommended for susceptibility testing of bacteria included in this EQAS 2017 component
conclusion of the susceptibility testing, the participants were asked to classify the isolates obtained according to the defined EFSA criteria for interpretation of ESBL/Ampc and/or carbapenemase producing isolates.

After the deadline, the qualitative results indicating if the samples were positive or negative for ESBL/AmpC, or carbapenemase-producing *E. coli* (OXA-48 and other), as well as the interpretations of the susceptibility tests results, and the conclusion on the observed *E. coli* phenotypes were evaluated against the expected results and scored as correct or incorrect. As no threshold is agreed the performance was evaluated case by case and not classified into acceptable or unacceptable based on the deviation percentage.

### 3. Results

Upon arrival of the parcels, the participants were requested to provide more information in a small introductory questionnaire on the database, including details on sample reception (measured temperature and date/time), the monitoring activities, and the methods used in their laboratory. As requested, the participating laboratories have, with one exception, returned the temperature loggers to the EURL. Here, the registration of the temperature was extracted and read to provide the temperature ranges along the shipment and at sample reception/opening. All samples were registered to be between -1°C and 2,5°C at arrival inferred from the temperature at opening time from the temperature logger registration and thereby all samples were expected to be in good conditions for testing at the time for opening of the parcels.

#### 3.1 Data omitted from the report

The total number of test results for ESBL/AmpC qualitative isolation considered for this report was 248 tests. As mentioned in the introduction, some deviations in the MIC results were seen by the EURL-AR, when the *E. coli* were re-isolated from the meat matrix. As the meat and caecal matrices have a natural background of bacteria from the animal itself and meat also from handling and processing, there is a risk for presence of *E. coli* and other *Enterobacteriaceae*. As such the strain M-3.4 exhibited a different, distinct phenotype in 14 labs (56%) out of the 25 labs that isolated this strain from meat, with analogous deviations in AZI, CHL, GEN, TET and TMP. Furthermore, other deviations for FEP, FOT, IMI occurred in 6-19 labs (25-75 %), resulting in omission of all tests for M-3.4. As such, the number of test results evaluated in this report is 217. The deviating phenotype is described in App. 3b.

Likewise, M-3.5 turned out to have a different resistance pattern in 27 of 31 countries (87 %), showing analogous deviating MIC results for CIP, NAL, SMX, TET and TMP. The results for these five antibiotics will not be evaluated as errors, and the results of this different phenotype are included in the table of expected resistance in Appendix 3b.

For the strain M-3.3/cefepime the expected interpretation was 'resistant', however 20 labs (67 %) found the strain sensitive to cefepime. All deviations were based on MIC values one step from the expected, but for this strain the MIC was close to the cut-off.
Table 2. The overall performance of ESBL/AmpC isolation and identification, 2017.

<table>
<thead>
<tr>
<th>Isolation of ESBL /AMPC from samples</th>
<th>Correctly classified samples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of performed tests</td>
<td>Number of correct tests</td>
</tr>
<tr>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>217</td>
<td>100</td>
</tr>
<tr>
<td>Number of expected negative tests</td>
<td>Number of correctly identified negative tests</td>
</tr>
<tr>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>62</td>
<td>29</td>
</tr>
<tr>
<td>Number of expected positive tests</td>
<td>Number of correctly identified positive tests</td>
</tr>
<tr>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>155</td>
<td>71</td>
</tr>
</tbody>
</table>

3.2 Methods used by EQAS-participants

All 33 participating laboratories, which have submitted results, participated in the ESBL and AmpC isolation and performed the identification and susceptibility of the respective isolates. Five laboratories reported that they did not perform the optional carbapenemases selective isolation. The number of qualitative isolation tests results reported was variable including results for three to eight samples, depending on how many samples were tested (a few participants only tested meat or caecal sample while most others tested both), for the antimicrobial susceptibility test it depended on how many isolates were found and further tested in the MIC panels.

Information on the methods used for isolation, identification and typing was collected from the participants through the database.

Most laboratories (n=32) reported that isolation had been performed following the exact procedures described in the protocol provided.

One lab reported using LB as enrichment medium for meat samples only. The species identification was performed equally using biochemical tests (n=10), MALDI TOF (n=9) or chromogenic agar plating (n=9), and PCR using specific targets to confirm the ID (n=4). Additionally some laboratories reported using second and third identification methods as supplement.

The broth microdilution testing was performed using the antimicrobials and ranges defined under the EU Commission regulation 652/2013 for testing the isolated and identified E. coli isolates using panel 1 (EUVSEC). Additional AST of the presumptive ESBL/AmpC and/or carbapenemase isolates was performed using panel 2 (EUVSEC2) if relevant and interpretation of the results according to the EFSA criteria for ESBL/AmpC and carbapenemase phenotypic classification.
3.3 ESBL /AmpC and carbapenemase producing E. coli isolation and identification

**ESBL/AmpC**

The total amount of test results was 217 tests for the ESBL/AmpC isolation qualitative results. In this trial, 29 participating NRLs reported results for all the eight samples sent. Two laboratories reported only results for the meat samples (Labs, #38, and #41) and two laboratories reported only results for the caecal samples (Labs #32 and #58). All in all 215 tests were correct, corresponding to 99.1% of correct results. From the 62 samples expected to be negative all were correctly assigned. Regarding the 155 samples expected to be found positive, all but two were correctly found positive. These two deviations were observed by Lab #23 that determined the meat sample M-3.3 and the caecal sample M-3.7 as negative (Table 2). One laboratory (#22) measured unexpected high MIC for IMI but not for MERO in sample M-3.7, and did thereby not have a clear phenotype, leading to the classification ‘Other phenotype’. Additional two laboratories (#6 and #41) reported elevated resistance to FOX in sample M-3.1, leading to the classification of ESBL + AmpC.

**Other carbapenemases and OXA-48**

The specific isolation of presumptive carbapenemase producing E. coli was performed by extending the protocol to include isolation on CARBA selective agar plates as described in the EURL-AR protocols. Five labs did not perform the optional carbapenemase selective isolation but defined results based on the findings with the in the ESBL/ampC selective method and AST results. The plates used for this purpose were chosen by the laboratories as the protocol defines that any suitable plates for selective isolation of carbapenemase- and OXA-48-producing E. coli may be used. Most participants declared the use of the chromogenic agar ChromID CARBA and ChromID OXA or CARBA Smart combination plates (as reported by eight and five participants, respectively). A total of 11 participants did not report the brand of plates being used for this purpose, even though they report the EURL-AR protocol was followed. As the carbapenemase producing isolate in sample 3.4 ended up with vast deviations in the phenotype, this has been excluded from the evaluation.

3.4 Antimicrobial susceptibility testing

A total of 3364 tests results were uploaded, excluding the omitted strain M-3.4, and 3332 (99.0 %) of these were correct. The 33 labs uploaded a variable number of results, depending on the samples found positive and isolates tested in one or both panels, ranging from 48 to 119 test results per participant.

The analysis per laboratory identified twenty-seven laboratories with no deviations while the others had deviation percentages ranging from 0.9 % to 1.6 %. (Figure 2). As the performance on the AST depends on the isolation and identification procedures, no threshold was set for acceptance as the capacity for performing AST of E. coli is analysed more accurately in the E. coli AST EQAS. However, the AST results have improved compared to the ESBL/AmpC EQAS performed in 2016.

In the analysis of deviations per antimicrobial, it was observed that the highest deviation percentage was found for cefotaxime (2.6 %) followed by cefoxitin and ciprofloxacin (1.3 %) (Figure 3).

The analysis of deviations per sample indicates that the highest deviation (3.0%, 20 deviations) was observed for sample M-3.3. All other samples had deviation levels below 1 % (Figure 4).
Figure 2. Deviations in antimicrobial susceptibility testing per participating laboratory.

Figure 3. Number of deviations per antimicrobial in EQAS matrix 2017 (AST results).

Figure 4. Number of deviations per sample in EQAS matrix 2017 (AST results).
3.5 ESBL/AmpC phenotypic testing conclusions

The sample M-3.1 contained ESBL producing CTX-M-65 and OXA-1; sample M-3.3 contained an isolate expressing AmpC phenotype by mutations in the AmpC promoter region; sample M-3.4 contained OXA-48, which mediates carbapenemase, but not ESBL phenotype. The samples M-3.5, M-3.6 and M-3.7 contained ESBL expressing isolates, mediated by CTX-M-32 and TEM-1B (M-3.5), CTX-M-15 (M-3.6) and SHV12 and TEM-1B (M-3.7). The remaining samples (M-3.2 and M-3.8) did not contain ESBL or AmpC presumptive isolates and were expected to be negative. The sample M-3.4 was totally excluded from evaluation due to multiple deviations in the phenotype, affecting the MIC results of five to eight different antibiotics and thereby also the ESBL/AmpC or carbapenemase phenotype. For sample M-3.5, there will be no evaluation on five antibiotics (CIP, NAL, SMX, TET and TMP), albeit not affecting the ESBL/AmpC or carbapenemase phenotype.

Hence, of 153 results uploaded and evaluated, 150 were correct (98.0 %) and three were deviating. These three cases included two instances of ESBL strain M-3.1 being classified as ‘Presumptive ESBL + pAmpC’ (Labs #6 and #41) and ESBL strain M-3.7 being classified as ‘Other phenotype’ (Lab #22).

Of 153 results uploaded, 150 were correct (98.0 %) and three were deviating. These three cases included two instances of ESBL strain M-3.1 being classified as ‘Presumptive ESBL + pAmpC’ (Labs #6 and #41) and ESBL strain M-3.7 being classified as ‘Other phenotype’ (Lab #22).
4. Discussion

4.1 ESBL and AmpC and carbapenemase-producing *E. coli* isolation and identification

The 2017 EURL-AR matrix EQAS trial was the third of its kind and it was conducted on samples of animal origin similar to those produced in the first round of this EQAS in 2015 (beef meat, pig caecal). Some challenges were met for the selection of test strains with abilities to survive in pig caecal samples, but choosing strains of the same origin proved to be beneficial. Thus, the ability of the plasmids carrying the relevant resistance genes to spread to background microorganisms in the matrix samples ended up being problematic, despite initial screening of the meat and caecal samples. It was specifically problematic for the meat samples, as two of the four spiked isolates turned out to be of different resistance phenotype after passage in meat. As the screening only serves to reveal possible ESBL/AmpC contamination and a rough estimation of the level of background bacteria, it is practically impossible to avoid having generic *Enterobacteriaceae* or *E. coli* in the meat matrix.

This is a great limitation for the matrix EQAS, compared to other EQAS’ on pure isolates. In general, the ESBL/AmpC isolation was successful, despite one lab that did not succeed to isolate two of the ESBL strains, one each from meat and caecal.

4.2 Antimicrobial susceptibility testing

The results uploaded were largely marked by the challenges to keep the resistance plasmid in the intended *E. coli* background, and the expected results were in several cases outnumbered by other, distinct resistance patterns. Thirty-one results were omitted from evaluation, mainly due to these changes. The remaining results, however, were generally very precise. In 2017, twenty-seven labs had no deviations in the evaluated AST results, compared to seven labs in 2016. The challenges met this year were not completely unexpected, as working with isolates in a matrix is not unlikely to cause problems in retrieving the right isolates from the samples, or changes could have occurred in the isolate composition in the samples or the isolate characteristics (conjugation, or plasmid losses). Some of the deviating results were further caused by MIC results close to breakpoint, and this should carefully be considered when selecting the strains for spiking samples.

4.3 ESBL /AmpC phenotypic testing conclusions

As what regards to the final conclusions for the AST testing and phenotypic confirmation, the conclusions depends heavily on the isolation process, thus some of the deviations might be related to the isolation of strains that have different characteristics. Thus, the primary AST results, used for classification of ESBL, AmpC, carbapenemases or other phenotypes were generally very good. In two instances, unexpected high cefoxitin MIC results led to deviating classification of ESBL strains as ESBL + AmpC (M-3.1), and one ESBL strain (M-3.7) was mis-classified as other phenotype.
5. Conclusion

In general, the results of this matrix EQAS demonstrate that most participating labs have well established methods to isolate ESBL and AmpC carrying strains from meat or caecal samples. One issue that can be commented is the amount of false positives in the selective isolation of carbapenemase-producing isolates, but the labs perform very well in identifying these as non-\textit{E. coli}. There is a need to strictly control the media and the procedures of the selective isolation to select ESBL and AmpC or carbapenemase-producing \textit{E. coli} and to do species identification with reliable methods to allow detection of all relevant isolates with increased sensitivity.

The susceptibility testing results were in general very satisfactory, when omitting the relatively high number of deviations from expected results due to a change in the phenotype after passage in the meat matrices.

6. References

7. Appendices

Appendix 1. Pre-notification EURL-AR EQAS matrix 2017
Appendix 2. List of participants
Appendix 3. Expected results
Appendix 3b. Deviating phenotype Sample M-3.4
Appendix 4. Protocol EQAS matrix 2017
Appendix 5. Examples of Test forms EQAS matrix 2017
EURL-AR EQAS pre-notification

EQAS 2017 FOR SELECTIVE ISOLATION OF E. COLI WITH PRESUMPTIVE ESBL, AMPC PHENOTYPES OR CARBAPENEMASES FROM MEAT OR CAECAL SAMPLES

The EURL-AR announces the launch of the third EQAS on matrix samples, providing the opportunity for proficiency testing which is considered an essential tool for the generation of reliable laboratory results of consistently good quality.

This EQAS consists of testing of eight samples for selective isolation of ESBL, AmpC or carbapenemase-presumptive E. coli.

This EQAS is specifically for NRL’s on antimicrobial resistance involved in the monitoring according to the EU Commission legislation 652/2013 and specifically processing meat and caecal samples in the specific monitoring for ESBL implemented in 2015. The laboratories designated to be NRL-AR will be contacted to confirm the addresses for the shipment of these samples. Participation is free of charge for all above-mentioned designated laboratories.

TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY

The content of the parcel is categorized as “UN3373, Biological Substance Category B”. Eight samples which might contain ESBL, AmpC or carbapenemase-producing E. coli included in a matrix of meat and/or caecal will be shipped. Please provide the EQAS coordinator with documents or other information that can simplify customs procedures (e.g. specific text that should be written on the proforma invoice). To avoid delays, we kindly ask you to send this information already at this stage.

TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE

Shipment of isolates and protocol: The isolates are expected to be shipped in the first week of November. The protocol for this proficiency test will soon be available for download from the website (http://eurl-ar.eu/208-eqas.htm)

Submission of results: Results must be submitted to the National Food Institute no later than December, 18th, 2017 via a password-protected website. Upon reaching the deadline, each participating laboratory is kindly asked to enter the password-protected website once again to download an automatically generated evaluation report.

EQAS report: A report summarising and comparing results from all participants will be issued. In the report, laboratories will be presented coded, which ensures full anonymity. The EURL-AR and the EU Commission, only, will have access to un-coded results. The report will be publicly available.

Next EQAS: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing of E. coli, staphylococci and enterococci which will be carried out in June, 2018.

Please contact me if you have comments or questions regarding the EQAS.

Sincerely,

Jette Kjeldgaard
<table>
<thead>
<tr>
<th>Meat</th>
<th>Caecal</th>
<th>Institute</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>x</td>
<td>x</td>
<td>Austrian Agency for Health and Food Safety</td>
<td>Austria</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Institute of Public Health</td>
<td>Belgium</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>National Diagnostic and Research Veterinary Institute</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Croatian Veterinary Institut</td>
<td>Croatia</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Veterinary Services</td>
<td>Cyprus</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>State Veterinary Institute Praha</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Danish Veterinary and Food Administration</td>
<td>Denmark</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Estonian Veterinary and Food Laboratory</td>
<td>Estonia</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Finnish Food Safety Authority EVIRA</td>
<td>Finland</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Agence nationale de sécurité sanitaire alimentation, environnement, travail</td>
<td>France</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Federal Institute for Risk Assessment</td>
<td>Germany</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Veterinary Laboratory of Chalkida</td>
<td>Greece</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Central Agricultural Office Veterinary Diagnostic Directorate</td>
<td>Hungary</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Institute For Experimental Pathology, University of Iceland, KELDUR</td>
<td>Iceland</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Central Veterinary Research Laboratory</td>
<td>Ireland</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Istituto Zooprophilattico Sperimentale delle Regioni Lazio e Toscana</td>
<td>Italy</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Institute of Food Safety, Animal Health and Environment BIOR</td>
<td>Latvia</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>National Food and Veterinary Risk Assessment Institute</td>
<td>Lithuania</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Laboratoire de Medecine Vétérinaire</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Public Health Laboratory</td>
<td>Malta</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Wageningen Bioveterinary Research (WBVR)</td>
<td>Netherlands</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>The Netherlands Food and Consumer Product Safety Authority*</td>
<td>Netherlands</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Veterinarinstituttet</td>
<td>Norway</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>National Veterinary Research Institute</td>
<td>Poland</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Instituto Nacional de Investigación Agraria e Veterinaria</td>
<td>Portugal</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Institute for Diagnosis and Animal Health</td>
<td>Romania</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Institute for Hygiene and Veterinary Public Health</td>
<td>Romania</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>State Veterinary and Food Institute (SVFI)</td>
<td>Slovakia</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>National Veterinary Institute</td>
<td>Slovenia</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Laboratorio Central de Veterinaria</td>
<td>Spain</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Centro Nacional de Alimentación (AECOSAN)</td>
<td>Spain</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Foodborne Zoonoses and Antimicrobial Resistance Unit (ZTA)*</td>
<td>Spain</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>National Veterinary Institute, SVA</td>
<td>Sweden</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Institute of Veterinary Bacteriology, Vetsuisse Faculty Bern</td>
<td>Switzerland</td>
</tr>
<tr>
<td>x</td>
<td>x</td>
<td>Animal Plant Health Agency</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

Designated NRL-AR by the competent authority of the member state
Non-NRL-AR enrolled by the EURL-AR
Not a Member State of the EU

* Submitted results were not included in the current report (one dataset per country, only)
<table>
<thead>
<tr>
<th>EURL strain</th>
<th>Species</th>
<th>MERO</th>
<th>COL</th>
<th>AMP</th>
<th>AZI</th>
<th>TAZ</th>
<th>CHL</th>
<th>CIP</th>
<th>FOT</th>
<th>GEN</th>
<th>NAL</th>
<th>SMX</th>
<th>TET</th>
<th>TMP</th>
<th>TGC</th>
<th>Genes</th>
<th>ESBL conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meat</td>
<td>E. coli</td>
<td>≤0.03</td>
<td>≤1</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>1</td>
<td>&gt;128</td>
<td>&gt;4</td>
<td>&gt;128</td>
<td>1</td>
<td>&gt;128</td>
<td>&gt;1024</td>
<td>&gt;64</td>
<td>&gt;32</td>
<td>≤0.25</td>
<td>≤0.25</td>
<td>OXA-1/CTX-M-65</td>
</tr>
<tr>
<td>Meat</td>
<td>E. coli</td>
<td>≤0.03</td>
<td>≤1</td>
<td>&gt;64</td>
<td>4</td>
<td>4</td>
<td>≤8</td>
<td>0.03</td>
<td>2</td>
<td>1</td>
<td>≤1</td>
<td>≤4</td>
<td>8</td>
<td>≤1</td>
<td>≤4</td>
<td>≤0.25</td>
<td>≤0.25</td>
</tr>
<tr>
<td>Meat</td>
<td>E. coli</td>
<td>0.25</td>
<td>≤1</td>
<td>&gt;64</td>
<td>&gt;4</td>
<td>≤0.5</td>
<td>128</td>
<td>≤0.015</td>
<td>≤0.25</td>
<td>≥32</td>
<td>≤0.015</td>
<td>≥4</td>
<td>≤0.5</td>
<td>≤4</td>
<td>≤0.25</td>
<td>≤0.25</td>
<td>OXA-48 (not ESBL)</td>
</tr>
<tr>
<td>Meat</td>
<td>E. coli</td>
<td>≤0.03</td>
<td>≤1</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>8</td>
<td>16</td>
<td>≤0.015</td>
<td>≥4</td>
<td>≤0.5</td>
<td>≤4</td>
<td>≤0.25</td>
<td>≤4</td>
<td>≤0.25</td>
<td>≤0.015</td>
<td>≤0.25</td>
<td>TEM-1B</td>
</tr>
<tr>
<td>Caecal</td>
<td>E. coli</td>
<td>≤0.03</td>
<td>≤1</td>
<td>&gt;64</td>
<td>&gt;8</td>
<td>128</td>
<td>&gt;4</td>
<td>≥0.5</td>
<td>≥1</td>
<td>≤0.5</td>
<td>≥4</td>
<td>≥128</td>
<td>≥1024</td>
<td>≥64</td>
<td>&gt;32</td>
<td>≤0.25</td>
<td>≤0.25</td>
</tr>
<tr>
<td>Caecal</td>
<td>E. coli</td>
<td>≤0.03</td>
<td>≤1</td>
<td>&gt;64</td>
<td>≥8</td>
<td>128</td>
<td>&gt;4</td>
<td>≥0.5</td>
<td>≥1</td>
<td>≤0.5</td>
<td>≥4</td>
<td>≥128</td>
<td>≥1024</td>
<td>≥64</td>
<td>&gt;32</td>
<td>≤0.25</td>
<td>≤0.25</td>
</tr>
<tr>
<td>Caecal</td>
<td>E. coli</td>
<td>≤0.03</td>
<td>≤1</td>
<td>&gt;64</td>
<td>&gt;4</td>
<td>≤8</td>
<td>16</td>
<td>≤2</td>
<td>≤0.25</td>
<td>≤0.25</td>
<td>≤2</td>
<td>≤0.25</td>
<td>≤0.25</td>
<td>≤0.25</td>
<td>≤0.25</td>
<td>≤0.25</td>
<td>Negative</td>
</tr>
</tbody>
</table>

**MIC interpretations**

<table>
<thead>
<tr>
<th>EURL strain</th>
<th>Species</th>
<th>MERO</th>
<th>COL</th>
<th>AMP</th>
<th>AZI</th>
<th>TAZ</th>
<th>CHL</th>
<th>CIP</th>
<th>FOT</th>
<th>GEN</th>
<th>NAL</th>
<th>SMX</th>
<th>TET</th>
<th>TMP</th>
<th>TGC</th>
<th>Genes</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meat</td>
<td>E. coli</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>ESBL</td>
</tr>
<tr>
<td>Meat</td>
<td>E. coli</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>AmpC</td>
</tr>
<tr>
<td>Meat</td>
<td>E. coli</td>
<td>R</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>OXA-48 not ESBL</td>
</tr>
<tr>
<td>Meat</td>
<td>E. coli</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>ESBL</td>
</tr>
<tr>
<td>Caecal</td>
<td>E. coli</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>ESBL</td>
</tr>
<tr>
<td>Caecal</td>
<td>E. coli</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>ESBL</td>
</tr>
<tr>
<td>Caecal</td>
<td>E. coli</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>ESBL</td>
</tr>
</tbody>
</table>

- Not tested - susceptible
- Resistant
<table>
<thead>
<tr>
<th>EURL strain</th>
<th>Species</th>
<th>FOX</th>
<th>ETP</th>
<th>IMI</th>
<th>MERO</th>
<th>TAZ</th>
<th>FEP</th>
<th>F/C</th>
<th>T/C</th>
<th>FOT</th>
<th>TRM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meat EURL-M-3.1</td>
<td>E. coli</td>
<td>4</td>
<td>≤ 0.015</td>
<td>0.25</td>
<td>≤ 0.03</td>
<td>1</td>
<td>2</td>
<td>≤0.06/4</td>
<td>≤0.12/4</td>
<td>64</td>
<td>4</td>
</tr>
<tr>
<td>Meat EURL-M-3.2</td>
<td>E. coli</td>
<td>32</td>
<td>≤ 0.015</td>
<td>0.25</td>
<td>≤ 0.03</td>
<td>4</td>
<td>0.12</td>
<td>1/4</td>
<td>4/4</td>
<td>2</td>
<td>16</td>
</tr>
<tr>
<td>Meat EURL-M-3.3</td>
<td>E. coli</td>
<td>8</td>
<td>0.5</td>
<td>2</td>
<td>0.5</td>
<td>0.12</td>
<td>0.25/4</td>
<td>0.25/4</td>
<td>0.25</td>
<td>128</td>
<td></td>
</tr>
<tr>
<td>Meat EURL-M-3.4</td>
<td>E. coli</td>
<td>4</td>
<td>≤ 0.015</td>
<td>≤ 0.12</td>
<td>≤ 0.03</td>
<td>8</td>
<td>32</td>
<td>≤0.06/4</td>
<td>≤0.12/4</td>
<td>&gt;64</td>
<td>8</td>
</tr>
<tr>
<td>Caecal EURL-M-3.6</td>
<td>E. coli</td>
<td>8</td>
<td>0.03</td>
<td>≤ 0.12</td>
<td>≤ 0.03</td>
<td>32</td>
<td>32</td>
<td>0.12/4</td>
<td>0.25/4</td>
<td>64</td>
<td>16</td>
</tr>
<tr>
<td>Caecal EURL-M-3.7</td>
<td>E. coli</td>
<td>8</td>
<td>0.03</td>
<td>0.25</td>
<td>≤ 0.03</td>
<td>32</td>
<td>0.5</td>
<td>≤0.06/4</td>
<td>0.25/4</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Caecal EURL-M-3.8</td>
<td>Negative</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### MIC interpretations

<table>
<thead>
<tr>
<th>EURL strain</th>
<th>Species</th>
<th>FOX</th>
<th>ETP</th>
<th>IMI</th>
<th>MERO</th>
<th>TAZ</th>
<th>FEP</th>
<th>F/C</th>
<th>T/C</th>
<th>FOT</th>
<th>TRM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meat EURL-M-3.1</td>
<td>E. coli</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>≤0.06/4</td>
<td>≤0.12/4</td>
<td>R</td>
<td>S</td>
</tr>
<tr>
<td>Meat EURL-M-3.2</td>
<td>E. coli</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>1/4</td>
<td>4/4</td>
<td>R</td>
<td>S</td>
</tr>
<tr>
<td>Meat EURL-M-3.3</td>
<td>E. coli</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>0.25/4</td>
<td>S</td>
<td>R</td>
<td>S</td>
</tr>
<tr>
<td>Meat EURL-M-3.4</td>
<td>E. coli</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>≤0.06/4</td>
<td>≤0.12/4</td>
<td>R</td>
<td>S</td>
</tr>
<tr>
<td>Caecal EURL-M-3.6</td>
<td>E. coli</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>0.12/4</td>
<td>0.25/4</td>
<td>R</td>
<td>S</td>
</tr>
<tr>
<td>Caecal EURL-M-3.7</td>
<td>E. coli</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>≤0.06/4</td>
<td>0.25/4</td>
<td>R</td>
<td>S</td>
</tr>
<tr>
<td>Caecal EURL-M-3.8</td>
<td>Negative</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Not tested - susceptible**
- **Resistant**
- **Not applicable**
## Overview of deviating results in samples M-3.4 and M-3.5

<table>
<thead>
<tr>
<th>EURL strain</th>
<th>MERO</th>
<th>COL</th>
<th>AMP</th>
<th>AZI</th>
<th>TAZ</th>
<th>CHL</th>
<th>CIP</th>
<th>FOT</th>
<th>GEN</th>
<th>NAL</th>
<th>SMX</th>
<th>TET</th>
<th>TMP</th>
<th>TGC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meat</td>
<td>EURL-M-3.4</td>
<td>0.25</td>
<td>≤1</td>
<td>&gt;64</td>
<td>8</td>
<td>≤0.5</td>
<td>8</td>
<td>≤0.015</td>
<td>0.5 - 2.0</td>
<td>0.5</td>
<td>≤4</td>
<td>&gt;1024</td>
<td>≤2</td>
<td>0.25</td>
</tr>
<tr>
<td>Meat</td>
<td>EURL-M-3.5</td>
<td>≤0.03</td>
<td>≤1</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>8</td>
<td>16</td>
<td>8</td>
<td>&gt;4</td>
<td>≤0.5</td>
<td>&gt;128</td>
<td>&gt;1024</td>
<td>&gt;64</td>
<td>&gt;32</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EURL strain</th>
<th>MERO</th>
<th>COL</th>
<th>AMP</th>
<th>AZI</th>
<th>TAZ</th>
<th>CHL</th>
<th>CIP</th>
<th>FOT</th>
<th>GEN</th>
<th>NAL</th>
<th>SMX</th>
<th>TET</th>
<th>TMP</th>
<th>TGC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meat</td>
<td>EURL-M-3.4</td>
<td>R</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S/R</td>
<td>R</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>Meat</td>
<td>EURL-M-3.5</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>S</td>
</tr>
</tbody>
</table>

**Resistant**

<table>
<thead>
<tr>
<th>EURL strain</th>
<th>FOX</th>
<th>ETP</th>
<th>IMI</th>
<th>MERO</th>
<th>TAZ</th>
<th>FEP</th>
<th>F/C</th>
<th>T/C</th>
<th>FOT</th>
<th>TRM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meat</td>
<td>EURL-M-3.4</td>
<td>8</td>
<td>0.5</td>
<td>0.25 - 0.5</td>
<td>0.5</td>
<td>0.25</td>
<td>0.25 - 1.0</td>
<td>0.25/4</td>
<td>0.25/4</td>
<td>0.5 - 2.0</td>
</tr>
<tr>
<td>Meat</td>
<td>EURL-M-3.5</td>
<td>4</td>
<td>≤0.015</td>
<td>≤0.12</td>
<td>≤0.03</td>
<td>8</td>
<td>32</td>
<td>≤0.06/4</td>
<td>≤0.12/4</td>
<td>&gt;64</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EURL strain</th>
<th>FOX</th>
<th>ETP</th>
<th>IMI</th>
<th>MERO</th>
<th>TAZ</th>
<th>FEP</th>
<th>F/C</th>
<th>T/C</th>
<th>FOT</th>
<th>TRM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meat</td>
<td>EURL-M-3.4</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>R</td>
<td>S</td>
<td>R</td>
<td>0.25/4</td>
<td>0.25/4</td>
<td>R</td>
</tr>
<tr>
<td>Meat</td>
<td>EURL-M-3.5</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>R</td>
<td>R</td>
<td>≤0.06/4</td>
<td>≤0.12/4</td>
<td>R</td>
</tr>
</tbody>
</table>

**Resistant**

**Not applicable**

Deviations marked in red
PROTOCOL
for selective isolation of presumptive ESBL-, AmpC- and carbapenemase-producing
Escherichia coli from meat and caecal samples (Matrix EQAS)

Table of contents

1 INTRODUCTION .................................................................................................................. 1
2 OBJECTIVES ........................................................................................................................ 2
3 OUTLINE OF THE EQAS ................................................................................................... 2
3.1 Shipping, receipt and storage of samples ................................................................ 2
3.2 Selective isolation of ESBL, AmpC or carbapenemase producing E. coli from the samples .................................................................................................................................. 3
3.3 Antimicrobial susceptibility testing ......................................................................... 4
4 REPORTING OF RESULTS AND EVALUATION .......................................................... 6
4.1 General recommendations for data upload ............................................................ 6
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE ............................ 7
5.1 Sample reception/testing ........................................................................................... 7
5.2 Selective enrichment methods .................................................................................. 7
5.3 Test results ................................................................................................................. 7
5.4 Finalizing data input, EQAS evaluation and approval of result upload .............. 8
APPENDIX ......................................................................................................................................... 9

1 INTRODUCTION

The organisation and implementation of an External Quality Assurance System (EQAS) on selective isolation of presumptive extended spectrum beta-lactamase (ESBL)-, AmpC- or carbapenemase-producing E. coli is among the tasks of the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR), and will include the selective isolation procedures and
antimicrobial susceptibility testing (AST) of obtained isolates of eight samples of either meat or caecal content. In 2017, these eight samples will include five 25-g samples of beef meat and three 1-g samples of pig caecal content. These samples may contain *E. coli* presumptive of producing either ESBL-, AmpC- or carbapenemase-enzymes.

It is expected that the participating laboratories apply the same analysis procedures used in the monitoring, described by the regulation EC/652/2013, and perform the selective isolation following the by EU recommended methods, published on the EURL-AR website [www.eurl-ar.eu](http://www.eurl-ar.eu).

### 2 OBJECTIVES

This EQAS aims to assess and, if necessary, to improve the quality of results obtained in the selective isolation of presumptive ESBL-, AmpC- or carbapenemase-producing isolates from meat and caecal samples. Further objectives are to evaluate and improve the comparability of surveillance data on ESBL-, AmpC- or carbapenemase-producing *E. coli* reported to EFSA by different laboratories.

### 3 OUTLINE OF THE EQAS

#### 3.1 Shipping, receipt and storage of samples

In November 2017, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will receive a parcel containing eight samples from the National Food Institute. All strains used in the spiking of samples belong to UN3373, Biological substance, category B. Participants should expect that ESBL-, AmpC- and/or carbapenemase-enzymes producing strains will be included in some of the sample matrices.

The samples will be spiked matrices of either beef meat or pig caecal content and will be distributed already weighed and ready to be tested, in tubes labelled from 3.1 to 3.8. Hereof 3.1 to 3.5 being samples of meat (each 25 g) and 3.6 to 3.8 being samples of caecal content (each 1 g).

The matrix samples will be shipped on November 6th in frozen state in separate tubes and contained in a cooling box with a temperature logging devices and cooling elements.

Upon arrival, it is very important to open the parcel as soon as possible and proceed to the analysis (following the normal procedures for sample testing in the monitoring).

**It is required that participants**

- when opening the parcel, note the date and exact time at opening (this data is very important to follow the temperature data checks)
- proceed to sample analysis immediately after opening the parcel
- register the date for start of analysis for each sample
- collect the temperature logging device (small discoid device located in a bag inserted in a labelled tube, located inside the parcel); open the tube and take out the bag with the
device inside. Place this bag with the device in the labelled bubble envelope provided and return it to the EURL-AR as soon as possible. Please note that you will have to arrange for stamps/postage (the post systems differ from country to country, why this cannot be arranged and paid from the EURL-AR in advance).

3.2 Selective isolation of ESBL, AmpC or carbapenemase producing *E. coli* from the samples

The samples provided in each parcel are weighed beforehand and therefore no further weighing is required. Proceed immediately to the first enrichment step by adding the sample to the necessary volume of media (225 ml of Buffered Peptone water for the meat samples and 9 ml for the caecal samples) as referred in the official EURL-AR protocols. All the following procedures should follow the methods used in the monitoring for ESBL and AmpC *E. coli* according to the EC/652/2013 regulation. If any changes are introduced to the official protocols, these changes should be described with details in the online database on the methods upload page. The participants are responsible for assuring the validity of the plates and therefore the protocol for “Validation of selective MacConkey agar plates supplemented with 1 mg/L cefotaxime for monitoring of ESBL and AmpC producing *E. coli* in meat and animals” should be run beforehand, as stated on the EURL-AR webpage (see http://eurl-ar.eu/233-protocols.htm).

Optionally, the participants may perform the additional plating for isolation of carbapenemase-producing *E. coli* from the samples, following the official protocols and plating on suitable agar plates. Similarly, the agar plates used for the carbapenemase isolation should be validated using the protocol for “Validation of selective and indicative agar plates for monitoring of carbapenemase-producing *E. coli*”.

The officially recommended protocols are found on the EURL-AR webpage (http://eurl-ar.eu/233-protocols.htm):

- Follow the protocol for meat when testing samples 3.1 to 3.5
- Follow the protocol for caecal content when testing samples 3.6 to 3.8

As referred in these protocols, the isolates obtained from isolation procedure should be identified as *E. coli* using the procedures for *E. coli* species identification applied at the participant’s laboratory for the specific monitoring of ESBL- and AmpC-producing *E.coli*.

Please store the isolates obtained in the isolation procedure and document the whole process as well as all the findings in each step.

As part of the results submission, you will be requested to describe the findings along the enrichment process and selective isolation including growth in the media, isolation of suspected colonies, species identification results and finally regarding the finding (or not) of presumptive *E. coli* isolates harbouring one of the selected resistances (this result will be evaluated in relation to the expected result as a qualitative result) (see details in the Test Form).
3.3 Antimicrobial susceptibility testing

If the sample is deemed positive for ESBL-, AmpC- or carbapenemase-producing *E. coli*, one *E. coli* isolate per sample should be taken further and tested for susceptibility to antimicrobials as stated in the EU regulation (antimicrobials listed in Tables 1 and 2 in this document).

Only one *E. coli* isolate is expected to be tested for AST and these results will be evaluated in the database comparing to expected results.

AST results to be reported should be from:

- A presumptive carbapenemase positive isolate (from the CARBA or OXA-48 selective plates), if this optional part was performed and a presumptive carbapenemase positive *E. coli* isolate was detected.
- An ESBL- or AmpC-presumptive isolate (if you do not have a carbapenemase positive isolate or if you did not perform the optional plating) if an ESBL- or AmpC-presumptive isolate was detected.

The testing should be performed using the same method as implemented in your laboratory for performing AST when monitoring for EFSA according to the regulation EC/652/2013 (using the two-step approach, i.e. both testing panels) and applying the interpretative criteria listed below.

Table 1. Antimicrobials recommended for AST of *Escherichia coli* and interpretative criteria according to table 1 in Commission Implementing Decision 2013/652/EU

<table>
<thead>
<tr>
<th>Antimicrobials for <em>E. coli</em></th>
<th>MIC (mg/L)</th>
<th>R is &gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampicillin, AMP</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Azithromycin, AZI</td>
<td>16*</td>
<td></td>
</tr>
<tr>
<td>Cefotaxime, FOT</td>
<td>0.25</td>
<td></td>
</tr>
<tr>
<td>Ceftazidime, TAZ</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Chloramphenicol, CHL</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin, CIP</td>
<td>0.064</td>
<td></td>
</tr>
<tr>
<td>Colistin, COL</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Gentamicin, GEN</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Meropenem, MERO</td>
<td>0.125</td>
<td></td>
</tr>
<tr>
<td>Nalidixic acid, NAL</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Sulfamethoxazole, SMX</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>Tetracycline, TET</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Tigecycline, TGC</td>
<td>0.5**</td>
<td></td>
</tr>
<tr>
<td>Trimethoprim, TMP</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

* Tentative ECOFF
** EUCAST.org
Plasmid-mediated quinolone resistance
When performing AST of *E. coli*, the interpretative criteria listed in Table 1 for results obtained by MIC-determination should allow detection of plasmid-mediated quinolone-resistant test strains.

Beta-lactam resistance
Confirmatory testing for ESBL production is mandatory on all strains resistant to cefotaxime (FOT), ceftazidime (TAZ) and/or meropenem (MERO) and should be performed by testing the second panel of antimicrobials (Table 2).

Table 2. Antimicrobials recommended for additional AST of *Escherichia coli* resistant to cefotaxime, ceftazidime or meropenem and interpretative criteria according to Table 4 in Commission Implementing Decision 2013/652/EU.

<table>
<thead>
<tr>
<th>Antimicrobials for <em>E. coli</em></th>
<th>MIC (mg/L)</th>
<th>R is &gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefepime, FEP</td>
<td>0.125</td>
<td></td>
</tr>
<tr>
<td>Cefotaxime, FOT</td>
<td>0.25</td>
<td></td>
</tr>
<tr>
<td>Cefotaxime + clavulanic acid (F/C)</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>Cefoxitin, FOX</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Ceftazidime, TAZ</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Ceftazidime+ clavulanic acid (T/C)</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>Ertapenem, ETP</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>Imipenem, IMI</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Meropenem, MERO</td>
<td>0.125</td>
<td></td>
</tr>
<tr>
<td>Temocillin, TRM</td>
<td>&gt;32*</td>
<td></td>
</tr>
</tbody>
</table>

*Tentative ECOFF

Confirmatory test for ESBL production requires use of both cefotaxime (FOT) and ceftazidime (TAZ) alone and in combination with a β-lactamase inhibitor (clavulanic acid). Synergy is defined either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in combination with clavulanic acid vs. the MIC of the agent when tested alone (MIC FOT : FOT/CL or TAZ : TAZ/CL ratio ≥ 8) (CLSI M100 Table 3A, Tests for ESBLs). The presence of synergy indicates ESBL production.

Confirmatory test for carbapenemase production requires the testing of meropenem (MERO).

Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type beta-lactamase.

The classification of the phenotypic results should be based on the most recent EFSA recommendations (EURL-AR Workshop 2016, [https://www.eurl-]
4 REPORTING OF RESULTS AND EVALUATION

Please write your results in the test forms, and enter your results into the interactive web database.

4.1 General recommendations for data upload

We recommend reading carefully the description reported in paragraph 5 before entering your results in the web database. **Results must be submitted no later than 18th, December, 2017.** After the deadline when all participants have uploaded results, you will be able to login to the database once again, and to view and print an automatically generated report evaluating your results. Results in agreement with the expected interpretation are categorised as ‘correct’, while results deviating from the expected interpretation are categorised as ‘incorrect’.

If you experience difficulties in entering your results, please contact us directly.

All results will be summarized in a report which will be publicly available. The data in the report will be presented with laboratory codes. A laboratory code is known to the individual laboratory, whereas the complete list of laboratories and their codes is confidential and known only to the EURL-AR and the EU Commission. All conclusions will be public.

If you have questions, please do not hesitate to contact the EQAS Coordinator:

Jette Sejer Kjeldgaard
National Food Institute
Technical University of Denmark
Kemitorvet, Building 204,
DK-2800 Lyngby
Denmark
Tel: +45 3588 6269
E-mail: jetk@food.dtu.dk
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE

Please read carefully this paragraph before entering the web page. Remember that you need by your side the completed test forms.

Enter the EURL-AR EQAS 2017 start web page (http://eurl.food.dtu.dk/matrix), write your username and password in lower-cases and press enter. Your username and password are indicated in the Welcome letter following the samples. Do not hesitate to contact us if you experience problems with the login.

You can browse back and forth by using the Home or back keys, but please remember to save your inputs before.

5.1 Sample reception/testing
Please fill in with information in relation to date and time (please note the exact time) and temperature at arrival of the parcel contents as measured by you (we will also check on the thermo-loggers data after you send back the device.

5.2 Selective enrichment methods
Please fill in with the details of the methods use and insert any changes made to the official method

5.3 Test results

5.3.1 Selective enrichment of presumptive ESBL-, AmpC- or carbapenemase -producing E. coli

Fill in the answers for the questions regarding the selective enrichment results along the process

5.3.2 Species identification enrichment of presumptive ESBL- or AmpC-producing E. coli

Please confirm the results and conclude if you found an E. coli presumptive of producing an ESBL or AmpC gene in the sample (this conclusion will be evaluated).

Please confirm the results and conclude also if you found an E. coli presumptive of producing a carbapenemase or OXA-type enzyme in the sample (these conclusions will be evaluated separately).

If you respond to the above questions indicating that you did not find a presumptive isolate to go further you are not expected to fill in the remaining questions.

If your answer is ‘yes’ for both or one of the above, you are expected to fill in the MIC tables and final conclusion of the AST and confirmatory testing.
5.3.3 AST of E. coli

Based on the first MIC panel results, indicate if the isolate fulfils the criteria to be tested on the second panel (confirmatory phenotypic testing) or not, and fill in the results for the second panel in case you decide to do the confirmatory testing.

Complete the fields in the result tables related to the results obtained.

Click on “save” and then go back using the tab “home” and enter another test page to upload results.

In the data entry pages, enter the obtained values and the interpretation (R, resistant or S, susceptible) for each E. coli isolate.

Remember to report also the conclusion of the phenotypic testing on the second panel (will be evaluated separately).

If you did not test for susceptibility to a given antimicrobial, please leave the field empty.

Click on “save“ and then go back using the tab “home” and enter another test page to upload results.

Click on “save“.

5.4 Finalizing data input, EQAS evaluation and approval of result upload

Review the input pages by browsing through the pages and make corrections if necessary.

Remember to save a page if you make corrections. If you press home a page without saving changes, you will see an error screen. In this case, click on “save“ to save your results, browse back to the page and then continue.

Please complete the evaluation form for the EQAS when you finalize the data input. You can find the tab on the Home page, on the tab “Evaluation”.

Before approving your input, please be sure that you have filled in all the relevant fields for the sample sheet, the methods and the test results for all samples tested because **YOU CAN ONLY APPROVE ONCE!** The approval blocks your data entry in the interactive database.
APPENDIX

Criteria for interpretation of *Escherichia coli*, panel 2 results

![Diagram of criteria for interpretation of *Escherichia coli*]

- **ESBL-Phenotype**
  - FOT or TAZ > 1 mg/L AND
  - MERO ≤ 0.12 mg/L AND
  - FOX ≤ 8 mg/L AND
  - SYN FOT/CLV and/or TAZ/CLV

- **AmpC-Phenotype**
  - FOT or TAZ > 1 mg/L AND
  - MERO ≤ 0.12 mg/L AND
  - FOX > 8 mg/L AND
  - No SYN FOT/CLV nor TAZ/CLV
  - (Not excluded presence of ESBLs)

- **ESBL + AmpC-Phenotype**
  - FOT or TAZ > 1 mg/L AND
  - MERO ≤ 0.12 mg/L AND
  - FOX > 8 mg/L AND
  - SYN FOT/CLV and/or TAZ/CLV

- **Carbapenemase-Phenotype**
  - MEROM > 0.12 mg/L
  - Needs confirmation
  - (Not excluded presence of ESBLs or AmpC)

- **Susceptible**
  - FOT-TAZ-FOX-MEM ≤ ECOFF

**Other phenotypes**

1) If FOT or TAZ > 1 mg/ml AND
   - MEM ≤ 0.12 mg/L AND
   - FOX ≤ 8 mg/L AND
   - NO SYN FOT/CLV nor TAZ/CLV
   - Not excluded CPs (consult EURL)

2) If FOT and/or TAZ ≤ 1 mg/L AND > ECOFF AND
   - MERO ≤ 0.12 mg/L
   - FOX ≤ 8 mg/L

3) If FOT and/or TAZ ≤ 1 mg/L
   - MERO ≤ 0.12 mg/L
   - FOX > 8 mg/L
   - *cAmpCs could be included here

4) If MERO ≤ 0.12 mg/L BUT
   - ETP > ECOFF AND/OR
   - IMI > ECOFF
   - Not excluded CPs, needs confirmation (consult EURL)

5) Any other combinations not described in previous boxes (contact EURL)

Test forms,
Isolation of ESBL/AmpC- and carbapenemase-producers from matrices

Username:
Contact person:
Country:
Date for filling in test forms:

SAMPLES

Reception date and exact time of opening the parcel of the proficiency test samples at the laboratory: (date and time is required)

Temperature of the contents of the parcel at arrival: °C

How many samples did your laboratory process in 2017 for monitoring of ESBL/AmpC-detection in relation to 2013/652/EU? (choose only one option)
- less than 100
- 101-200
- 201-300
- 301-400
- 401-1000
- more than 1000

Which kind of samples did your laboratory process in 2017 for monitoring of ESBL/AmpC-detection in relation to 2013/652/EU? (you may choose more than one option)
- caecal, pig
- meat, beef
- other matrices, please specify:
Did you process samples for carbapenemase-selective isolation?
- Yes
- No

How many samples did your laboratory process in 2017 for monitoring of carbapenemases in relation to 2013/652/EU? (Choose only one option)
- less than 100
- 101-200
- 201-300
- 301-400
- 401-1000
- more than 1000

Which kind of samples did your laboratory process in 2017 for monitoring of carbapenemase-production in relation to 2013/652/EU? (you may choose more than one option)
- caecal, pig
- meat, beef
- other matrices, please specify:

Any other comments:
METHODS

1- Method used for selective isolation of ESBL/AmpC in this EQAS:

Selective isolation procedure using the EURL recommended protocols that refer to the EU regulation 652/2013/EU

☐ The protocol was used without modifications (please jump to question 2)
☐ The protocol was used, however, the pre-enrichment was modified (please respond question 1.1)
☐ The protocol was used, however, the selective isolation procedures were modified (please respond question 1.2)
☐ The protocol was used, however, the incubation conditions in the selective plating were modified (please respond question 1.3)

1.1- If you modified the pre-enrichment, please indicate the differences introduced:

Different sample amount (weight) used for the enrichment procedure:
- g in meat samples
- g for caecal samples

Different volume of enrichment in the isolation step:
- ml for meat samples
- ml for caecal samples

Different pre-enrichment medium:

Different incubation conditions in pre-enrichment °C/ h;

Please justify these changes:

1.2- If you made changes in the selective isolation procedure:

Different sample amount (weight) used for the enrichment procedure:
- g in meat samples
- g for caecal samples

Different concentration of cefotaxime: mg/L

Different antimicrobial

Different medium

Please justify these changes:
1.3- If you used different incubation conditions in the selective plating, please indicate the conditions used: °C/ h;

Please justify these changes:

2- Method used for selective isolation of carbapenemase-producers (in case you run this method) in this EQAS:

Selective isolation procedure using the EURL recommended protocols for isolation of carbapenemase-producers:

☐ We did not perform carbapenemase selective isolation
☐ The protocol was used without modifications
☐ The protocol was modified

Plates used (brand/type)

Please justify these changes:

3- Method used for confirmation of *E. coli* species identification. Please indicate the primary *E. coli* identification method used (choose only one option; if you used more than one method, please explain in the comments field)

☐ PCR using published methods
☐ PCR using in-house method
☐ Biochemical tests
☐ MALDI-ToF
☐ DNA Sequencing
☐ Chromogenic media

Comments:

4- Method used for general antimicrobial susceptibility testing of the strains (choose only one option)

☐ Microbroth dilution test on EUVSEC panel
☐ Microbroth dilution test on another panel
☐ Agar dilution method
☐ E-test
☐ Disk diffusion test
5- Method used for phenotypic confirmatory testing of ESBL/AmpC (choose only one option)

☐ Microbroth dilution test on EUVSEC2 panel
☐ Microbroth dilution test on another panel
☐ Agar dilution method
☐ E-test
☐ Disk diffusion test

6- Additional comments. Please include here description and justification of your choice if you modified something in relation to the method defined in the EU regulation 2013/652/EU:
TEST FORM – SAMPLE ‘EURL M-3.X’

Date the isolation procedure was started:

Please describe the results you have observed regarding this sample:

Visible growth in pre-enrichment:
Yes ☐ / No ☐

Growth on ESBL/AmpC-selective plates:
Yes ☐ / No ☐

Please describe the growth observed on ESBL/AmpC-selective plates? (choose only one option)
☐ Mixed culture containing typical E. coli colonies
☐ Mixed culture without typical E. coli colonies
☐ Pure culture of typical E. coli colonies
☐ Pure culture without typical E. coli colonies
☐ No growth

Results of species identification: (choose only one option)
☐ No isolates tested (sample negative)
☐ Presumptive ESBL/AmpC isolate identified as E. coli (sample considered positive)

Comments:

Did you perform carbapenemase selective plating?
Yes ☐ / No ☐

Growth on CARBA-selective plates:
Yes ☐ / No ☐

Growth on OXA-48 selective plates:
Yes ☐ / No ☐

Results of species identification (isolates from carbapenemase selective plating): (choose only one option)
☐ No isolates tested (sample negative)
☐ Presumptive other carbapenemase isolate identified as E. coli (sample considered positive)
☐ Presumptive OXA-48 isolate identified as E. coli (sample considered positive)

Comments:

If you have found a presumptive carbapenemase positive isolate, please insert the results of antimicrobial susceptibility testing for the selected E. coli isolate, if you do not have a carbapenemase positive isolate and you have an ESBL presumptive isolate, please insert the results for this isolate (only one E.coli isolate is expected to be tested and these results will be evaluated in our database against the expected results).
Please confirm where the isolate tested for antimicrobial susceptibility originated from (compulsory):

☐ ESBL/ampC isolation on MacConkey with cefotaxime
☐ CARBA plate
☐ OXA-48 plate

Based on the results from the first AST panel, was the isolate found resistant to cefotaxime, ceftazidime or meropenem so that the second panel was tested?

Yes ☐ / No ☐
### AST results

<table>
<thead>
<tr>
<th>Strain</th>
<th>Antimicrobial</th>
<th>Results and interpretation</th>
<th>MIC-value (mg/L)</th>
<th>S / R</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. coli</em> EURL M-3.X</td>
<td>Ampicillin, AMP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Azithromycin, AZI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cefotaxime, FOT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ceftazidime, TAZ</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chloramphenicol, CHL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ciprofloxacin, CIP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Colistin, COL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gentamicin, GEN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Meropenem, MERO</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nalidixic acid, NAL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sulfamethoxazole, SMX</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tetracycline, TET</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tigecycline, TGC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trimethoprim, TMP</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Second *E. coli* AST panel (confirmatory testing for ESBL/AmpC/carbapenemase-production)

<table>
<thead>
<tr>
<th>Strain</th>
<th>Antimicrobial</th>
<th>Results and interpretation</th>
<th>MIC-value (mg/L)</th>
<th>S / R</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. coli</em> EURL M-3.X</td>
<td>Cefpime, FEP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cefotaxime + clavulanic acid (F/C)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cefotaxime, FOT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cefoxitin, FOX</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ceftazidime, TAZ</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ceftazidime+ clavulanic acid (T/C)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ertapenem, ETP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Imipenem, IMI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Meropenem, MERO</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Temocillin, TRM</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Conclusions of confirmatory phenotypic testing:** (choose only one option and please note that the final result will be evaluated by the database)

**Interpretation of PANEL 2 results:**

- Presumptive ESBL
- Presumptive AmpC
- Presumptive carbapenemase
- Other phenotype
- Susceptible

**Comments (include optional genotype or other results):**